Stephen G. Divers

1.9k total citations · 2 hit papers
14 papers, 1.2k citations indexed

About

Stephen G. Divers is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Stephen G. Divers has authored 14 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 8 papers in Cancer Research and 5 papers in Oncology. Recurrent topics in Stephen G. Divers's work include Cancer Genomics and Diagnostics (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Genetic factors in colorectal cancer (4 papers). Stephen G. Divers is often cited by papers focused on Cancer Genomics and Diagnostics (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Genetic factors in colorectal cancer (4 papers). Stephen G. Divers collaborates with scholars based in United States, Canada and Hong Kong. Stephen G. Divers's co-authors include Richard B. Lanman, Randall F. Holcombe, Hans J. Berkel, Terry C. Davis, Suman Pramanik, Davey B. Daniel, Daniel Dix, Karen L. Reckamp, Justin I. Odegaard and Ray D. Page and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Stephen G. Divers

14 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

2015 470 citations Richard B. Lanman, Stefanie Mortimer et al. PLoS ONE profile →
Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

2019 408 citations Natasha B. Leighl, Ray D. Page et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen G. Divers United States	9	778	649	418	281	239	14	1.2k
Jacob J. Adashek United States	24	416 0.5×	506 0.8×	816 2.0×	338 1.2×	143 0.6×	106	1.5k
J.-Y. Douillard France	15	475 0.6×	891 1.4×	1.0k 2.4×	264 0.9×	252 1.1×	59	1.8k
Agnès J. van de Wouw Netherlands	21	554 0.7×	511 0.8×	1.3k 3.2×	142 0.5×	273 1.1×	56	1.7k
Erin Hofstatter United States	21	612 0.8×	252 0.4×	812 1.9×	500 1.8×	203 0.8×	60	1.9k
Vernon Harvey New Zealand	22	489 0.6×	357 0.6×	1.3k 3.1×	258 0.9×	84 0.4×	44	1.8k
David Watkins United Kingdom	22	254 0.3×	446 0.7×	747 1.8×	322 1.1×	201 0.8×	81	1.4k
Aafke H. Honkoop Netherlands	17	495 0.6×	364 0.6×	1.1k 2.7×	189 0.7×	207 0.9×	33	1.5k
John D. Sprandio United States	15	236 0.3×	251 0.4×	371 0.9×	262 0.9×	34 0.1×	27	989
Kathryn F. Mileham United States	14	273 0.4×	724 1.1×	863 2.1×	324 1.2×	91 0.4×	54	1.3k
Francesco Nuzzo Italy	15	351 0.5×	355 0.5×	710 1.7×	229 0.8×	56 0.2×	48	1.2k

Countries citing papers authored by Stephen G. Divers

Since Specialization

Citations

This map shows the geographic impact of Stephen G. Divers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen G. Divers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen G. Divers more than expected).

Fields of papers citing papers by Stephen G. Divers

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen G. Divers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen G. Divers. The network helps show where Stephen G. Divers may publish in the future.

Co-authorship network of co-authors of Stephen G. Divers

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen G. Divers. A scholar is included among the top collaborators of Stephen G. Divers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen G. Divers. Stephen G. Divers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Luckett, Daniel J., Cesar A. Perez, Judy S. Wang, et al.. (2023). Abstract 921: Identification of NRG1 fusions in patients with solid tumors: analysis from a real-world community oncology network. Cancer Research. 83(7_Supplement). 921–921. 1 indexed citations

Luckett, Daniel J., Marilyn Holt, Suzanne F. Jones, et al.. (2023). Clinical and molecular presentation of KRAS G12D-mutated pancreatic ductal adenocarcinoma in real-world settings.. Journal of Clinical Oncology. 41(4_suppl). 738–738. 1 indexed citations

Page, Ray D., Leylah Drusbosky, Victoria M. Raymond, et al.. (2021). Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non–Small Cell Lung Cancer. Clinical Lung Cancer. 23(1). 72–81. 31 indexed citations

Page, Ray D., Leylah Drusbosky, Victoria M. Raymond, et al.. (2021). Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma.. Journal of Clinical Oncology. 39(15_suppl). 9027–9027. 1 indexed citations

Leighl, Natasha B., Ray D. Page, Victoria M. Raymond, et al.. (2019). Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer. Clinical Cancer Research. 25(15). 4691–4700. 408 indexed citations breakdown →

Leighl, Natasha B., Ray D. Page, Victoria M. Raymond, et al.. (2019). Abstract 4460: Clinical utility of comprehensive cell-free DNA (cfDNA) analysis to identify genomic biomarkers in newly diagnosed metastatic non-small cell lung cancer (mNSCLC). 4460–4460. 3 indexed citations

Lima, Caio Max S. Rocha, Patrick J. Roberts, Victor Priego, et al.. (2017). Trilaciclib (G1T28): A cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC)—Phase 1b results.. Journal of Clinical Oncology. 35(15_suppl). 8568–8568. 8 indexed citations

Lanman, Richard B., Stefanie Mortimer, Oliver A. Zill, et al.. (2015). Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS ONE. 10(10). e0140712–e0140712. 470 indexed citations breakdown →

Divers, Stephen G., Louise Provencher, Shiuh‐Wen Luoh, et al.. (2010). Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy. Breast Cancer Research and Treatment. 123(3). 837–842. 15 indexed citations

10.

Divers, Stephen G., Louise Provencher, Shiuh‐Wen Luoh, et al.. (2009). Phase II study of sagopilone (ZK-Epo) in patients with recurrent metastatic breast cancer (MBC). Journal of Clinical Oncology. 27(15_suppl). 1083–1083. 6 indexed citations

11.

Divers, Stephen G., et al.. (2005). Phase I/IIa Study of Cisplatin and Gemcitabine As Induction Chemotherapy Followed by Concurrent Chemoradiotherapy With Gemcitabine and Paclitaxel for Locally Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 23(27). 6664–6673. 12 indexed citations

12.

Davis, Terry C., Hans J. Berkel, Randall F. Holcombe, Suman Pramanik, & Stephen G. Divers. (1998). Informed Consent for Clinical Trials: a Comparative Study of Standard Versus Simplified Forms. JNCI Journal of the National Cancer Institute. 90(9). 668–674. 226 indexed citations

13.

Kannan, K., Stephen G. Divers, A. Lurie, et al.. (1995). Cell surface expression of lysosome‐associated membrane protein‐2 (lamp2) and CD63 as markers ofin vivoplatelet activation in malignancy. European Journal Of Haematology. 55(3). 145–151. 21 indexed citations

14.

Divers, Stephen G., K. Kannan, R. Malcolm Stewart, et al.. (1995). Quantitation of CD62, soluble CD62, and lysosome‐associated membrane proteins 1 and 2 for evaluation of the quality of stored platelet concentrates. Transfusion. 35(4). 292–297. 43 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact